Heartseed, World's First Clinical Trial of Catheter Administration of iPSC-Derived Cardiomyocyte Spheroids: First Patient Dosed

TOKYO--(BUSINESS WIRE)-- #Heartseed--Heartseed dosed the 1st patient in its trial of HS-005, the world's 1st catheter delivery of iPSC-derived cardiomyocyte spheroids for heart failure.